Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001

Kazunari Tateishi, Hidenori Mizugaki, Yasuyuki Ikezawa, Ryo Morita, Keiki Yokoo, Toshiyuki Sumi, Mari Aso, Hajime Kikuchi, Atsushi Nakamura, Motoki Sekikawa, Fumiaki Yoshiike, Yasuo Kitamura, Nozomu Kimura, Tsutomu Hachiya, Kyoji Tsurumi, Toshihiko Agatsuma, Furuta Megumi, Keiichi Nakamura, Daisuke Jingu, Hiroshi Yamamoto, Makoto Kosaka, Hiroshi Yokouchi

Open source

DOI: 10.1093/jjco/hyae168
Published: 2024-12-04
Container: Japanese Journal of Clinical Oncology
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/jjco/hyae168,
  title = {Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001},
  author = {Kazunari Tateishi and Hidenori Mizugaki and Yasuyuki Ikezawa and Ryo Morita and Keiki Yokoo and Toshiyuki Sumi and Mari Aso and Hajime Kikuchi and Atsushi Nakamura and Motoki Sekikawa and Fumiaki Yoshiike and Yasuo Kitamura and Nozomu Kimura and Tsutomu Hachiya and Kyoji Tsurumi and Toshihiko Agatsuma and Furuta Megumi and Keiichi Nakamura and Daisuke Jingu and Hiroshi Yamamoto and Makoto Kosaka and Hiroshi Yokouchi},
  year = {2024},
  journal = {Japanese Journal of Clinical Oncology},
  doi = {10.1093/jjco/hyae168},
  url = {https://doi.org/10.1093/jjco/hyae168}
}

RIS

TY  - JOUR
TI  - Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001
AU  - Kazunari Tateishi
AU  - Hidenori Mizugaki
AU  - Yasuyuki Ikezawa
AU  - Ryo Morita
AU  - Keiki Yokoo
AU  - Toshiyuki Sumi
AU  - Mari Aso
AU  - Hajime Kikuchi
AU  - Atsushi Nakamura
AU  - Motoki Sekikawa
AU  - Fumiaki Yoshiike
AU  - Yasuo Kitamura
AU  - Nozomu Kimura
AU  - Tsutomu Hachiya
AU  - Kyoji Tsurumi
AU  - Toshihiko Agatsuma
AU  - Furuta Megumi
AU  - Keiichi Nakamura
AU  - Daisuke Jingu
AU  - Hiroshi Yamamoto
AU  - Makoto Kosaka
AU  - Hiroshi Yokouchi
PY  - 2024
JO  - Japanese Journal of Clinical Oncology
DO  - 10.1093/jjco/hyae168
UR  - https://doi.org/10.1093/jjco/hyae168
ER  -

APA

Tateishi, K., Mizugaki, H., Ikezawa, Y., Morita, R., Yokoo, K., Sumi, T., Aso, M., Kikuchi, H., Nakamura, A., Sekikawa, M., Yoshiike, F., Kitamura, Y., Kimura, N., Hachiya, T., Tsurumi, K., Agatsuma, T., Megumi, F., Nakamura, K., Jingu, D., Yamamoto, H., Kosaka, M., & Yokouchi, H. (2024). Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae168

Source records

crossref · retrieved 2026-09-26T14:29:46.452Z